Elucid presented ELUCIDATE results at TCT 2026, a multicenter retrospective validation of its FDA cleared FFR-IQ BioIntegrated FFR-CT software in 491 vessels from 347 patients at 11 U.S. and European sites, with invasive measurements reviewed by the Cardiovascular Research Foundation core lab. The study met both primary endpoints with 92.2 percent sensitivity, 93.1 percent specificity and 92.9 percent vessel level accuracy versus invasive FFR, and 84.1 percent accuracy (AUC 0.879) in the 0.75 to 0.85 gray zone. The cohort had no overlap with model development or internal testing data, and the model was locked before validation.
Our readCardiology and imaging buyers comparing FFR-CT options get core lab adjudicated accuracy figures, including gray zone performance near the 0.80 treatment threshold where FFR-CT results drive cath lab referral decisions.